Moss ML - Search Results

1

The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.

Moss ML, Bomar M, Liu Q, Sage H, Dempsey P, Lenhart PM, Gillispie PA, Stoeck A, Wildeboer D, Bartsch JW, Palmisano R, Zhou P. Moss ML, et al. J Biol Chem. 2007 Dec 7;282(49):35712-21. doi: 10.1074/jbc.M703231200. Epub 2007 Sep 25. J Biol Chem. 2007. PMID: 17895248 Free article.

2

Therapeutic benefits from targeting of ADAM family members.

Moss ML, Bartsch JW. Moss ML, et al. Biochemistry. 2004 Jun 15;43(23):7227-35. doi: 10.1021/bi049677f. Biochemistry. 2004. PMID: 15182168 Review.

3

Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8.

Naus S, Reipschläger S, Wildeboer D, Lichtenthaler SF, Mitterreiter S, Guan Z, Moss ML, Bartsch JW. Naus S, et al. Among authors: moss ml. Biol Chem. 2006 Mar;387(3):337-46. doi: 10.1515/BC.2006.045. Biol Chem. 2006. PMID: 16542157 Free article.

4

ADAM10 as a target for anti-cancer therapy.

Moss ML, Stoeck A, Yan W, Dempsey PJ. Moss ML, et al. Curr Pharm Biotechnol. 2008 Feb;9(1):2-8. doi: 10.2174/138920108783497613. Curr Pharm Biotechnol. 2008. PMID: 18289051 Review.

5

ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.

Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna M, Zhong JL, Dingwall C, Ferdous T, Schlomann U, Zhou P, Griffith LG, Lauffenburger DA, Petrovich R, Bartsch JW. Moss ML, et al. J Biol Chem. 2011 Nov 25;286(47):40443-51. doi: 10.1074/jbc.M111.280495. Epub 2011 Sep 28. J Biol Chem. 2011. PMID: 21956108 Free PMC article.

6

The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10.

Lemieux GA, Blumenkron F, Yeung N, Zhou P, Williams J, Grammer AC, Petrovich R, Lipsky PE, Moss ML, Werb Z. Lemieux GA, et al. Among authors: moss ml. J Biol Chem. 2007 May 18;282(20):14836-44. doi: 10.1074/jbc.M608414200. Epub 2007 Mar 27. J Biol Chem. 2007. PMID: 17389606 Free PMC article.

7

ADAM10 as a therapeutic target for cancer and inflammation.

Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. Crawford HC, et al. Among authors: moss ml. Curr Pharm Des. 2009;15(20):2288-99. doi: 10.2174/138161209788682442. Curr Pharm Des. 2009. PMID: 19601831 Review.

8

Fluorescent substrates useful as high-throughput screening tools for ADAM9.

Moss ML, Rasmussen FH, Nudelman R, Dempsey PJ, Williams J. Moss ML, et al. Comb Chem High Throughput Screen. 2010 May;13(4):358-65. doi: 10.2174/138620710791054259. Comb Chem High Throughput Screen. 2010. PMID: 20015014

9

A colorimetric-based amplification system for proteinases including MMP2 and ADAM8.

Moss ML, Koller G, Bartsch JW, Rakow S, Schlomann U, Rasmussen FH. Moss ML, et al. Anal Biochem. 2015 Sep 1;484:75-81. doi: 10.1016/j.ab.2015.05.011. Epub 2015 May 27. Anal Biochem. 2015. PMID: 26026386

10

Tumor necrosis factor-alpha (TNF-alpha) regulates shedding of TNF-alpha receptor 1 by the metalloprotease-disintegrin ADAM8: evidence for a protease-regulated feedback loop in neuroprotection.

Bartsch JW, Wildeboer D, Koller G, Naus S, Rittger A, Moss ML, Minai Y, Jockusch H. Bartsch JW, et al. Among authors: moss ml. J Neurosci. 2010 Sep 8;30(36):12210-8. doi: 10.1523/JNEUROSCI.1520-10.2010. J Neurosci. 2010. PMID: 20826683 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page